
BMS appoints Thomas Lynch to board
pharmafile | December 16, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, lynch
Bristol-Myers Squibb has elected Thomas Lynch to its board to serve as a member on its Science and Technology Committee from January.
Lynch is currently the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, US.
From 1993 to 2009 Lynch was a professor of medicine at Harvard medical school and chief of haematology/oncology at Massachusetts general hospital cancer centre.
“Tom is both a world class oncologist and a highly accomplished business leader. As we advance our work in immuno-oncology and build our leadership position in oncology, his guidance and scientific and business perspectives will be invaluable,” said Lamberto Andreotti, chief executive of BMS.
James Cornelius, BMS’ chairman added: “We are very pleased to have Tom join our board. His rare combination of skills and track record of success in both medicine and business uniquely qualify him to serve on our board of directors.”
Related Content

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …






